Siponimod

CHEMBL2336071 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
516.6 g/mol
LogP
4.8
Phase
4

Siponimod is a selective sphingosine-1-phosphate receptor modulator (S1P1 and S1P5) used for the treatment of active secondary progressive multiple sclerosis (SPMS). By binding to S1P1 receptors on lymphocytes, it causes their sequestration in lymph nodes, reducing pathogenic lymphocyte migration into the CNS and associated neuroinflammation and demyelination. Its selectivity for S1P5, expressed on oligodendrocytes and NK cells, may provide additional neuroprotective effects relevant to SPMS progression.

Molecular Weight

516.6000 g/mol

LogP

4.80

TPSA

62.10 Ų

Lipinski RO5

Pass

Therapeutic Areas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1

InChI

InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)/b33-19+

Molecular Formula

C29H35F3N2O3

HBD / HBA

1 / 8

Rotatable Bonds

9

Heavy Atoms

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Siponimod is a selective sphingosine-1-phosphate receptor modulator (S1P1 and S1P5) used for the treatment of active secondary progressive multiple sclerosis (SPMS). By binding to S1P1 receptors on lymphocytes, it causes their sequestration in lymph nodes, reducing pathogenic lymphocyte migration into the CNS and associated neuroinflammation and demyelination. Its selectivity for S1P5, expressed on oligodendrocytes and NK cells, may provide additional neuroprotective effects relevant to SPMS progression.

Yes, Siponimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2336071. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 44599207. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.